

GP1644
Attorney's Docket No.: 10274-003003
List of Seq

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lobb et al.
Serial No. : 09/251,073
Filed : February 16, 1999
Title : TREATMENT FOR ASTHMA

Art Unit : 1644
Examiner : P. Gambel

RECEIVED

APR 18 2001

TECH CENTER 1600/2900
4/26/01**Box Sequence**

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated March 13, 2001 (copy enclosed), Applicants submit herewith a substitute paper copy of the Sequence Listing as required under 37 CFR §1.823(a) and a Request Under 37 C.F.R. §13821(e) To Transfer Computer Readable Form. Applicant respectfully requests entry of the paper copy of the Sequence Listing filed herewith for the instant application. Furthermore, Applicant request entry of the following amendments.

In the specification:

Replace the paragraph beginning at page 6, line 21 with the following rewritten paragraph:

A' --Several anti-VLA-4 monoclonal antibodies have been previously described (see, e.g., Sanchez-Madrid et al., 1986 [16]; Hemler et al. (1987) [17]; Pulido et al. (1991) [19]). For the experiments herein, an anti-VLA-4 monoclonal antibody designated HP1/2 (obtained from Biogen, Inc., Cambridge, MA) was used. The variable regions of the heavy and light chains of the anti-VLA-4 antibody HP1/2 have been cloned, sequenced and expressed in combination with constant regions of human immunoglobulin heavy and light chains. Such chimeric HP1/2

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 10, 2001

Date of Deposit

Signature

Jennifer H. Payne

Typed or Printed Name of Person Signing Certificate